skip to primary navigationskip to content

Healx secures £1.5m from Amadeus Capital and investors to combat rare diseases

last modified Oct 05, 2016 03:46 PM
Amadeus Capital Partners, the global technology investor, has made an early-stage investment of £1.5 million in ideaSpace alumni Healx, a Cambridge based healthcare company that seeks new uses for existing drugs in the fight against rare diseases.
Healx secures £1.5m from Amadeus Capital and investors to combat rare diseases

Dr Tim Guilliams, Healx CEO

Healx, founded and based in Cambridge, operates in the fast-growing drug ‘repurposing’ sector. The company uses advanced data analytics, including machine learning and computational biology techniques, alongside scientific literature analysis, to identify novel drug applications for rare diseases that afflict some 350 million people worldwide. Their unique model engages directly with patient advocacy groups, allowing them to lead the way in personalised healthcare for rare diseases.

Hermann Hauser, Partner and co-Founder of Amadeus Capital Partners, said, “Healx has taken advances in machine learning, data mining and analytics and combined them with deep pharma and life sciences expertise to address a growing need in the healthcare sector. With huge pressure on R&D budgets, drug repositioning will be essential in the fight against rare diseases. With this investment, Healx will take up a leadership position in the drug repurposing sector, expected to be worth over $31 billion by 2020.”

Healx has a scalable technology platform which allows it to match potential treatments to rare conditions and patients. Thanks to its data mining approach, the company aims to complete its drug repurposing studies within six months, much faster than historical literature-based studies.

While there are around 8,000 rare diseases – disorders affecting fewer than 1 in 2,000 people in Europe – only about 500 have a cure. Many are linked to genetics and children account for some 75% of identified cases. Healx has won contracts from major medical foundations in the US and Europe to find drug candidates to treat conditions including childhood diseases, Barth syndrome and Fragile-X.

Sales of ‘orphan’ drugs designed to treat a specific rare condition have been growing following changes in regulation and tax incentives in the US, with the market forecast to reach $178 billion in 2020. However, as only a small proportion of the population is affected by a particular rare disease, the justification for investing large sums in clinical trials remains a barrier to innovation.

Tim Guilliams, Chief Executive, Healx, commented: “Studies into rare medical conditions have long failed to receive adequate funding. By repurposing existing drugs to combat rare diseases, Healx is able to find potential treatments at a fraction of the cost and in a much shorter timeframe than developing a new drug. With this investment, Healx will have the resources to expand our technology platform and accelerate our drug review process to find treatments to many more devastating illnesses.”

To read more information, click here.

RSS Feed Latest news

Mixcloud signs milestone licensing deal with Warner Music

Oct 10, 2017

The future of radio is here

Changing the world: one fingerprint at a time

Oct 02, 2017

Simprints uses £270k to pioneer baby fingerprint scanner

The writing's on the wall: Blackboard win WOW Award

Sep 18, 2017

Ally recognised for impact on student success

Your liver on a microchip - a revolution in drug development

Aug 17, 2017

Funding for a cutting edge alternative to animal testing

An interview with Steve Marsh from GeoSpock

Aug 17, 2017

Steve talks extreme data and building the tech of the future

View all news